Advocate Children's Hospital Park Ridge

Clinical research site in Park Ridge, Illinois · Advocate Children's Hospital - Park Ridge, 1675 Dempster St, Park Ridge, IL 60068 · (847) 723-2210 · Website

As of July 2026, 18 paid clinical trials are recruiting at Advocate Children's Hospital Park Ridge in Park Ridge, Illinois. Active studies at this site cover conditions such as B Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Ganglioneuroblastoma, Nodular. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Advocate Children's Hospital Park Ridge (18)

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

for Ulcerative Colitis

14 locations incl. Phoenix

Sponsor: Takeda

Sex: All·Age: 2 - 17

Code: NCT06405087·Phase 3·Recruiting·Listed May 2024

Apply to this trial

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

for Ulcerative Colitis

8 locations incl. Mobile

Sponsor: Takeda

Sex: All·Age: 2+

Code: NCT05442567·Phase 3·Recruiting·Listed Jul 2022

Apply to this trial

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

for Crohn's Disease (CD)

15 locations incl. Phoenix

Sponsor: Takeda

Sex: All·Age: 2 - 17

Code: NCT04779320·Phase 3·Recruiting·Listed Mar 2021

Apply to this trial

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

for Childhood Extracranial Germ Cell Tumor

387 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT03067181·Phase 3·Recruiting·Listed Mar 2017

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

382 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for Hematopoietic and Lymphatic System Neoplasm

192 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: Female·Age: Up to 39

Code: NCT06513962·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

188 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting·Listed May 2019

Apply to this trial

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

for B Acute Lymphoblastic Leukemia

141 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 366 Days - 46

Code: NCT06124157·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

171 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT04293562·Phase 3·Recruiting·Listed Mar 2020

Apply to this trial

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

for Acute Lymphoblastic Leukemia

156 locations incl. Birmingham

Sponsor: PedAL BCU, LLC

Sex: All·Age: Up to 22

Code: NCT04726241·Phase 1, Phase 2·Recruiting·Listed Jan 2021

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

153 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

for Acute Leukemia of Ambiguous Lineage

112 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 365 Days

Code: NCT06317662·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Project: Every Child for Younger Patients With Cancer

for Adrenal Gland Pheochromocytoma

233 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 25

Code: NCT02402244·Recruiting·Listed Mar 2015

Apply to this trial

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

for Anaplastic Kidney Wilms Tumor

171 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 30

Code: NCT04322318·Phase 2·Recruiting·Listed Mar 2020

Apply to this trial

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

for Stage I Mixed Cell Type Kidney Wilms Tumor

146 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 30

Code: NCT06401330·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

for Embryonal Rhabdomyosarcoma

163 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT05304585·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

145 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting·Listed Apr 2017

Apply to this trial

Standardized Application of Feeding Evaluations Using SMART Tool

for Infant and Young Child Feeding

14 locations incl. Barrington

Sponsor: Wake Forest University Health Sciences

Sex: All·Age: Up to 1

Code: NCT07136610·Recruiting·Listed Aug 2025

Apply to this trial

More research sites in Park Ridge

Advocate Lutheran General Hospital (56 trials)
Advocate Children's Hospital-Park Ridge (14 trials)
Advocate Aurora Research Institute (3 trials)
AMR Park Ridge (2 trials)
Advocate Aurora Health (2 trials)
Advocate Children's Hospital (2 trials)
Advocate Lutheran General Childrens Hospital (2 trials)
Advocate Medical Group Adult Down Syndrome Center (2 trials)
Research (2 trials)
Advocate Children's Hospital - Park Ridge - PIN (1 trial)

Explore more

Paid clinical trials in Park Ridge, IL · Illinois clinical trials